Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case series.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kröger Kai, Lohmann Sebastian, Oertel Michael, Borchmann Peter, Kerkhoff Andrea, Lenz Georg, Stegger Lars, Eich Hans Theodor
Аннотация
PURPOSE: Positron-emission tomography combined with computed tomography (PET/CT) is the diagnostic standard for patients with Hodgkin's lymphoma. Positron-emission tomography combined with magnetic resonance imaging (PET/MRI) is an alternative diagnostic modality that reduces radiation exposure to the patient. This study aims to evaluate the potential merits of PET/MRI compared to PET/CT for target delineation for radiotherapy of Hodgkin's lymphoma.
METHODS: Five patients with newly diagnosed Hodgkin's lymphoma underwent PET/CT imaging directly followed by PET/MRI imaging as part of initial staging. Both modalities were subsequently compared regarding each patient's diagnosed involved nodal regions. Three of these patients received radiotherapy after the completion of chemotherapy. In the radiotherapy planning CT, different gross tumor volumes and clinical target volumes were contoured for both PET/CT and PET/MRI and quantitatively compared using the Dice coefficient.
RESULTS: No differences regarding the diagnosed disease stage were observed. The delineated tumor and target volumes showed minor differences without clinical significance.
CONCLUSION: Positron-emission tomography/MRI is a viable option to assure adequate staging and later target delineation in patients with Hodgkin's lymphoma. Due to the reduction of radiation exposure compared to PET/CT, it might be the preferable option if readily available.
METHODS: Five patients with newly diagnosed Hodgkin's lymphoma underwent PET/CT imaging directly followed by PET/MRI imaging as part of initial staging. Both modalities were subsequently compared regarding each patient's diagnosed involved nodal regions. Three of these patients received radiotherapy after the completion of chemotherapy. In the radiotherapy planning CT, different gross tumor volumes and clinical target volumes were contoured for both PET/CT and PET/MRI and quantitatively compared using the Dice coefficient.
RESULTS: No differences regarding the diagnosed disease stage were observed. The delineated tumor and target volumes showed minor differences without clinical significance.
CONCLUSION: Positron-emission tomography/MRI is a viable option to assure adequate staging and later target delineation in patients with Hodgkin's lymphoma. Due to the reduction of radiation exposure compared to PET/CT, it might be the preferable option if readily available.